|
|
|
|
|
01.10.25 - 15:06
|
GSK Is ′Betting Big′ on the US, CEO Walmsley Says (Bloomberg)
|
|
|
GSK is “betting big on the US” and engaged in "constructive" talks on drug pricing with President Donald Trump's administration, according to Emma Walmsley, the outgoing chief executive officer of the British drugmaker. Pfizer Inc.'s pricing deal with Trump is a “step forward and it's progress,” Walmsley said at Bloomberg's Women, Money & Power event in London. (Source: Bloomberg)...
|
|
|
01.10.25 - 14:48
|
GSK CEO Walmsley on Leading in Volatile Era (Bloomberg)
|
|
|
Emma Walmsley, CEO, GSK discusses how a global business is managing today's volatile economic and regulatory environment with Bloomberg's Ruth David at the Bloomberg Women, Money & Power 2025 event in London. (Source: Bloomberg)...
|
|
|
|
|
|
|
01.10.25 - 11:42
|
AKTIEN IM FOKUS 2: US-Deal mit Pfizer hilft gesamter Pharmabranche (DPA-AFX)
|
|
|
Nach Darstellung von Trump sollen weitere Vereinbarungen mit anderen Pharmagesellschaften folgen. Der Deal von Pfizer könnte einen Weg für die Konkurrenz aufzeigen, im Gegenzug für deutliche Preissenkungen Schlimmeres zu verhindern, kommentierte Evan Seigerman von BMO Capital Markets. Als bemerkenswert hob ein weiterer Analyst hervor, dass Pfizer in der Pressemitteilung zu der Einigung keinerlei Auswirkungen auf die Finanzkennziffern und den Ausblick erwähnt habe. Die Pfizer-Aktien legten nach der Einigung mit Trump am Dienstag um 6,8 Prozent zu. Im Gegenzug der Preisermäßigungen für Medicaid werden die neuen US-Branchenzölle für den Konzern für drei Jahre ausgesetzt...
|
|
|
|
|
|
|
29.09.25 - 22:09
|
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026 (GlobeNewswire EN)
|
|
|
SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced today that its Board of Directors approved plans to explore separating its business into two independent, publicly traded companies, each poised for strong, sustainable growth. Referred to as “Royalty Management Co” and as “Biopharma Co” in this press release, the two companies' different business models enable investors to align their investment philosophies and portfolio allocation with the strategic opportunities and financial objectives of each company.“Anaptys is strategically positioned with multiple attractive, high-potential assets, including our development-stage pipeline consisting of rosnilimab, ANB033 and ANB101, as well as substantial potential royalties and milestones payments from our ongoing financial collaborations with GSK and Vanda,” said Daniel Faga, president and chief executive officer ...
|
|
|
29.09.25 - 20:12
|
Emma Walmsley steadied GSK – but doubts linger over growth targets (The Guardian)
|
|
|
The outgoing chief executive reshaped the drugmaker, yet scepticism persists over promised revenuesGSK's Emma Walmsley to step down as chief executive after eight years“I am a change agent,” declared Emma Walmsley soon after she became chief executive of GlaxoSmithKline in 2017 and, sure enough, the UK's second largest pharmaceutical company does indeed look different from eight years ago.The consumer health division has gone – it was demerged as Haleon in 2023, which ended the debate about whether GSK required a bigger break-up. And annual budgets for research and development in pharmaceuticals and vaccines have been doubled in her time, which got to the core of the drugmaker's ills. Continue reading......
|
|
|
|
|
29.09.25 - 16:36
|
GSK′s Emma Walmsley to be step down as chief executive after eight years (The Guardian)
|
|
|
Chief commercial officer Luke Miels to take over as CEO at Britain's second-biggest drugmaker in surprise moveBusiness live – latest updatesBritain's second-biggest drugmaker GSK has announced the surprise departure of its chief executive, Emma Walmsley, after eight years in the top job.Walmsley, who has run the FTSE 100 company since 2017, will step down from the board at the end of this year, and remain at the business until her notice period ends on 30 September 2026. Continue reading......
|
|
|
|
|
|
|
|
|
29.09.25 - 13:24
|
Moldova Pro-EU Party Set to Win Election, Gold Price Climbs Above $3,800 | The Opening Trade 9/29 (Bloomberg)
|
|
|
Gold climbed to a record above $3,800 an ounce as precious metals surged, boosted by a weaker dollar as investors weighed a potential US government shutdown. A shutdown would threaten the release of key data including Friday's payrolls report, which economists expect would show subdued jobs growth in September.
Elsewhere in markets, shares in the UK's second largest drugmaker GSK rose on the announcement CEO Emma Walmsley is to step down after almost 9 years at the helm. She is to be succeeded by the firm's chief commercial officer Luke Miels.
The Opening Trade has everything you need to know as markets open across Europe. With analysis you won't find anywhere else, we break down the biggest stories of the day and speak to top guests who have skin in the game. Hosted by Kriti Gupta, Tom Mackenzie and Valerie Tytel. (Source: Bloomberg)...
|
|
|
29.09.25 - 12:18
|
GSK Taps Miels as CEO With Walmsley Stepping Down (Bloomberg)
|
|
|
GSK Plc Chief Executive Officer Emma Walmsley is stepping down after almost nine years and will be succeeded by the British drugmaker's chief commercial officer, Luke Miels, who will take over on Jan. 1. Ashley Furlong reports on Bloomberg Television. (Source: Bloomberg)...
|
|
|
29.09.25 - 12:03
|
GSK Underweight (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für GSK anlässlich des angekündigten Wechsels an der Führungsspitze mit einem Kursziel von 1400 Pence auf "Underweight" belassen. Die Ernennung des bisherigen Marketing- und ......
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
